Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (“CSC”) announced today the submission of a Phase III protocol to the U.S. Food and Drug Administration (“FDA”) for a randomized, double-blind study in metastatic melanoma. The multicenter trial will examine the effectiveness of CSC’s patient specific cancer immunotherapy in patients with recurrent stage III or stage IV metastatic melanoma.
Help employers find you! Check out all the jobs and post your resume.
